A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder

Journal of the American Academy of Child and Adolescent Psychiatry

Volumn 51, Issue 7, 2012, Pages 733-741

  Harfterkamp, Myriam ^a   Van De Loo Neus, Gigi ^b   Minderaa, Ruud B ^a   Van Der Gaag, Rutger Jan ^b   Escobar, Rodrigo ^d   Schacht, Alexander ^e   Pamulapati, Sireesha ^e   Buitelaar, Jan K ^b,c   Hoekstra, Pieter J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d ELI LILLY AND COMPANY   (Spain)

^e ELI LILLY AND COMPANY   (United States)

Author keywords

ADHD; ASD; atomoxetine; placebo controlled

Indexed keywords

ATOMOXETINE; PLACEBO;

ADHD RATING SCALE; ADOLESCENT; APPETITE; ARTICLE; ATTENTION DEFICIT DISORDER; AUTISM; CHILD; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONNERS TEACHER RATING SCALE REVISED SHORT FORM; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; EARLY MORNING AWAKENING; FATIGUE; FEMALE; HUMAN; MALE; NAUSEA; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHOOL CHILD; SIDE EFFECT; SLEEP DISORDER;

ADOLESCENT; ADRENERGIC UPTAKE INHIBITORS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; COMORBIDITY; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; PERSONALITY ASSESSMENT; PROPYLAMINES; PSYCHOMETRICS;

EID: 84862644371     PISSN: 08908567     EISSN: 15275418     Source Type: Journal    
DOI: 10.1016/j.jaac.2012.04.011     Document Type: Article

References (32)

1. Holtmann M, Bolte S, Poustka F. Attention deficit hyperactivity disorder symptoms in pervasive developmental disorders: association with autistic behavior domains and coexisting psychopathology. Psychopathology. 2007;40:172-177.
2. Gadow KD, DeVincent CJ, Pomeroy J. ADHD symptom subtypes in children with pervasive developmental disorder. J Autism Dev Disord. 2006;36:271-283.
3. Nijmeijer JS, Hoekstra PJ, Minderaa RB, et al. PDD symptoms in ADHD, an independent familial trait? J Abnorm Child Psychol. 2009;37:443-453.
4. Spencer TJ. Issues in the management of patients with complex attention-deficit hyperactivity disorder symptoms. CNS Drugs. 2009;23(Suppl 1):9-20.
5. Research Units on Pediatric Psychopharmacology Autism Network. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Arch Gen Psychiatry. 2005;62:1266-1274.
6. Aman MG, Arnold LE, McDougle CJ, et al. Acute and long-term safety and tolerability of risperidone in children with autism. J Child Adolesc Psychopharmacol. 2005;15:869-884.
7. Shea S, Turgay A, Carroll A, et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics. 2004;114:e634-e641.
8. Marcus RN, Owen R, Kamen L, et al. A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry. 2009;48:1110-1119.
9. Owen R, Sikich L, Marcus RN, Corey-Lisle P, et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics. 2009;124:1533-1540.
10. Troost PW, Althaus M, Lahuis BE, et al. Neuropsychological effects of risperidone in children with pervasive developmental disorders: a blinded discontinuation study. J Child Adolesc Psychopharmacol. 2006;16:561-573.
11. Aman MG, Hollway JA, McDougle CJ, et al. Cognitive effects of risperidone in children with autism and irritable behavior. J Child Adolesc Psychopharmacol. 2008;18:227-236.
12. Posey DJ, Puntney JI, Sasher TM, Kem DL, McDougle CJ. Guanfacine treatment of hyperactivity and inattention in pervasive developmental disorders: a retrospective analysis of 80 cases. J Child Adolesc Psychopharmacol. 2004;14:233-241.
13. Kratochvil CJ, Heiligenstein JH, Dittmann R, et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry. 2002;41:776-784.
14. Spencer T, Biederman J, Wilens T, et al. Effectiveness and tolerability of atomoxetine in adults with attention deficit hyperactivity disorder. Am J Psychiatry. 1998;155:693-695.
15. Weiss M, Tannock R, Kratochvil C, et al. A randomized, placebocontrolled study of once-daily atomoxetine in the school setting in children with ADHD. J Am Acad Child Adolesc Psychiatry. 2005;44:647-655.
16. Jou RJ, Handen BL, Hardan AY. Retrospective assessment of atomoxetine in children and adolescents with pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2005;15:325-330.
17. Troost PW, Steenhuis MP, Tuynman-Qua HG, et al. Atomoxetine for attention-deficit/hyperactivity disorder symptoms in children with pervasive developmental disorders: a pilot study. J Child Adolesc Psychopharmacol. 2006;16:611-619.
18. Posey DJ, Wiegand RE, Wilkerson J, Maynard M, Stigler KA, McDougle CJ. Open-label atomoxetine for attention-deficit/hyperactivity disorder symptoms associated with high-functioning pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2006;16:599-610.
19. Arnold LE, Aman MG, Cook AM, et al. Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial. J Am Acad Child Adolesc Psychiatry. 2006;45:1196-1205.
20. Faries DE, Yalcin I, Harder D, Heiligenstein JH. Validation of the ADHD Rating Scale as a clinician administered and scored instrument. J Atten Disord. 2001;5:107-115.
21. Rutter M, Le Couteur A, Lord C. ADI-R: The Autism Diagnostic Interview-Revised. Los Angeles, CA: Western Psychological Services.
22. DuPaul GJ, Anastopoulos AD, Power TJ, Reid R, Ikeda MJ, McGoey KE. Parent ratings of attention-deficit/hyperactivity disorder symptoms: factor structure and normative data. J Psychopathol Behav Assess. 1998;20:83-102.
23. Conners CK, Sitarenios G, Parker JD, Epstein JN. Revision and restandardization of the Conners Teacher Rating Scale (CTRS-R): factor structure, reliability, and criterion validity. J Abnorm Child Psychol. 1998;26:279-291.
24. Guy W. ECDEU assessment manual of Psychofarmacology. Rockville, MD: US Dept of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health: 1976. NIMH publication 76-338.
25. Eli Lilly and Co. Summary of product characteristics. Basingstoke, Hampshire, United Kingdom: Strattera; 2008.
26. Svanborg P, Thernlund G, Gustafsson PA, Hägglöf B, Poole L, Kadesjö B. Efficacy and safety of atomoxetine as add-on to psychoeducation in the treatment of attention deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled study in stimulant-naïve Swedish children and adolescents. Eur Child Adolesc Psychiatry. 2009;18:240-249.
27. Biederman J, Gao H, Rogers AK, Spencer TJ. Comparison of parent and teacher reports of attention-deficit/hyperactivity disorder symptoms from two placebo-controlled studies of atomoxetine in children. Biol Psychiatry. 2006;60:1106-1110.
28. Geller D, Donnelly C, Lopez F, et al. Atomoxetine treatment for pediatric patients with attention-deficit/hyperactivity disorder with comorbid anxiety disorder. J Am Acad child Adolesc Psychiatry. 2007;46:9,1119-1127.
29. Michelson D, Faries D, Wernicke J, et al., Atomoxetine ADHD Study Group. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics. 2001;108:e83.
30. Michelson D, Allen AJ, Busner J, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry. 2002;159:1896-1901.
31. Montoya A, Hervas A, Cardo E, et al. Evaluation of atomoxetine for first-line treatment of newly diagnosed, treatment-naive children and adolescents with attention deficit/hyperactivity disorder. Curr Med Res Opin. 2009;25:2745-2754.
32. Faraone SV, Biederman J, Zimmerman B. Correspondence of parent and teacher reports in medication trials. Eur Child Adolesc Psychiatry. 2005;14:20-27.